Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma's Kappa Opioid Agonist Peptide, JT-09 November 2, 2020
Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering October 28, 2020
Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09 October 28, 2020
Titan Pharmaceuticals Announces Pricing of $2.7 Million Registered Direct Offering September 24, 2020
Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation September 18, 2020
Titan's Probuphine® Commercialization Partner, Molteni, Enters Into Exclusive European Distribution Agreement With Accord Healthcare September 15, 2020
